BRAF-mutations in non-small cell lung cancer

Lung Cancer

Volumn 84, Issue 1, 2014, Pages 36-38

  Brustugun, Odd Terje ^a,b   Khattak, Asma Malik ^a   Trømborg, Anette Kjoshagen ^a   Beigi, Marzieh ^a   Beiske, Klaus ^a   Lund Iversen, Marius ^a   Helland, Åslaug ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

BRAF mutation; EGFR mutation; Genetic testing; Lung cancer; Tyrosine kinase inhibitors

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; GLUTAMIC ACID; K RAS PROTEIN; VALINE;

ADENOSQUAMOUS CARCINOMA; ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CANCER PATIENT; CANCER TISSUE; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; FEMALE; GENE EXPRESSION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG ADENOSQUAMOUS CARCINOMA; LUNG CARCINOMA; LUNG LARGE CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUTATION RATE; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SMOKING; TISSUE SECTION; UNIVERSITY HOSPITAL; VERY ELDERLY; YOUNG ADULT;

BRAF-MUTATION; EGFR-MUTATION; GENETIC TESTING; LUNG CANCER; TYROSINE KINASE INHIBITORS;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROTO-ONCOGENE PROTEINS B-RAF; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RISK FACTORS; TRANSLOCATION, GENETIC; YOUNG ADULT;

EID: 84896707216     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.01.023     Document Type: Article

References (15)

1. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
2. Wan P.T., Garnett M.J., Roe S.M., Lee S., Niculescu-Duvaz D., Good V.M., et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004, 116:855-867.
3. Oxnard G.R., Binder A., Jänne P.A. New targetable oncogenes in non-small-cell lung cancer. J Clin Oncol 2013, 31:1097-1104.
4. Peters S., Michielin O., Zimmermann S. Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma. J Clin Oncol 2013, 31:e341-e344.
5. Gautschi O., Pauli C., Strobel K., Hirschmann A., Printzen G., Aebi S., et al. A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib. J Thorac Oncol 2012, 7:e23-e24.
6. Cardarella S., Ogino A., Nishino M., Butaney M., Shen J., Lydon C., et al. Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. Clin Cancer Res 2013, 19:4532-4540.
7. Marchetti A., Felicioni L., Malatesta S., Grazia Sciarrotta M., Guetti L., Chella A., et al. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol 2011, 29:3574-3579.
8. Paik P.K., Arcila M.E., Fara M., Sima C.S., Miller V.A., Kris M.G., et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol 2011, 29:2046-2051.
9. Schmid K., Oehl N., Wrba F., Pirker R., Pirker C., Filipits M. EGFR/KRAS/BRAF-mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases. Clin Cancer Res 2009, 15:4554-4560.
10. Gautschi O., Peters S., Zoete V., Aebersold-Keller F., Strobel K., Schwizer B., et al. Lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib. Lung Cancer 2013, 82:365-367.
11. Sagerup C.M., Småstuen M., Johannesen T.B., Helland Å., Brustugun O.T. Sex-specific trends in lung cancer incidence and survival: a population study of 40,118 cases. Thorax 2011, 66:301-307.
12. Gahr S., Stoehr R., Geissinger E., Ficker J.H., Brueckl W.M., Gschwendtner A., et al. EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice. Br J Cancer 2013, 109:1821-1828.
13. Sen B., Peng S., Tang X., Erickson H.S., Galindo H., Mazumdar T., et al. Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib. Sci Transl Med 2012, 4. 136ra170.
14. Rudin C.M., Hong K., Streit M. Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer. J Thorac Oncol 2013, 8:e41-e42.
15. Alrifai D., Popat S., Ahmed M., Gonzalez D., Nicholson A.G., Parcq J., et al. A rare case of squamous cell carcinoma of the lung harbouring ALK and BRAF activating mutations. Lung Cancer 2013, 80:339-340.